{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:23:13Z","timestamp":1792790593547,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-breast-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.clbc.2024.05.001","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T03:22:22Z","timestamp":1715311342000},"page":"575-584.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparison of the Pathological Complete Response Rate and Survival Between HER2-Low and HER2-Zero Breast Cancer in Neoadjuvant Chemotherapy Setting: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"24","author":[{"given":"Mei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengsheng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixiao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingxiu","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.clbc.2024.05.001_bib0001","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.05.001_bib0002","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2024.05.001_bib0003","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1200\/JCO.19.02318","article-title":"Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study","volume":"38","author":"Modi","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2024.05.001_bib0004","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clbc.2024.05.001_bib0005","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.clbc.2024.05.001_bib0006","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1470-2045(21)00301-6","article-title":"Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials","volume":"22","author":"Denkert","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2024.05.001_bib0007","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejca.2022.08.031","article-title":"Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy","volume":"176","author":"Kang","year":"2022","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.clbc.2024.05.001_bib0008","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jamaoncol.2022.7476","article-title":"Clinicopathologic characteristics and prognosis of ERBB2-low breast cancer among patients in the national cancer database","volume":"9","author":"Peiffer","year":"2023","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.clbc.2024.05.001_bib0009","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3390\/cancers15041157","article-title":"Prognoses of patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer receiving neoadjuvant chemotherapy before surgery: a retrospective analysis","volume":"15","author":"Zhang","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.clbc.2024.05.001_bib0010","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.3390\/cancers14102509","article-title":"Impact of HER2 status on pathological response after neoadjuvant chemotherapy in early triple-negative breast cancer","volume":"14","author":"Domergue","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.clbc.2024.05.001_bib0011","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10549-021-06365-7","article-title":"HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer","volume":"190","author":"de Moura Leite","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2024.05.001_bib0012","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejca.2022.09.017","article-title":"Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers","volume":"176","author":"de Nonneville","year":"2022","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.clbc.2024.05.001_bib0013","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s12094-022-03062-9","article-title":"The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer","volume":"25","author":"Wang","year":"2023","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.clbc.2024.05.001_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.999716","article-title":"Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: a real-world retrospective study","volume":"12","author":"Tang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.clbc.2024.05.001_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1086480","article-title":"Evolution and clinical significance of HER2-low status after neoadjuvant therapy for breast cancer","volume":"13","author":"Shang","year":"2023","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.clbc.2024.05.001_bib0016","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s12282-022-01431-4","article-title":"HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC","volume":"30","author":"Li","year":"2023","journal-title":"Breast Cancer"},{"issue":"1","key":"10.1016\/j.clbc.2024.05.001_bib0017","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41523-022-00434-w","article-title":"HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment","volume":"8","author":"Miglietta","year":"2022","journal-title":"NPJ Breast Cancer"},{"issue":"9","key":"10.1016\/j.clbc.2024.05.001_bib0018","doi-asserted-by":"crossref","first-page":"5653","DOI":"10.1245\/s10434-023-13311-y","article-title":"Clinical genetic features and neoadjuvant chemotherapy response in HER2-low breast cancers: a retrospective, multicenter cohort study","volume":"30","author":"Yang","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2024.05.001_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.breast.2022.12.006","article-title":"Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer","volume":"67","author":"Zhou","year":"2023","journal-title":"Breast"},{"issue":"Supplement 4","key":"10.1016\/j.clbc.2024.05.001_bib0020","first-page":"1","article-title":"HER2-low status and response to neoadjuvant chemotherapy in early breast cancer","volume":"8","author":"Alkan","year":"2023","journal-title":"ESMO"},{"issue":"Supplement 16","key":"10.1016\/j.clbc.2024.05.001_bib0021","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2022.40.16_suppl.558","article-title":"Real-world clinical outcomes in patients with local\/regional HER2-low breast cancer: an NCDB analysis","volume":"40","author":"Jiang","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Supplement 4","key":"10.1016\/j.clbc.2024.05.001_bib0022","first-page":"PS4","article-title":"Prevalence of HER2-low and HER2-zero subgroups and correlation with response to neoadjuvant chemotherapy (NACT) in patients with HER2-negative breast cancer","volume":"81","author":"Reinert","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2024.05.001_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2023.152125","article-title":"Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer","volume":"64","author":"Qiao","year":"2023","journal-title":"Ann Diagn Pathol"},{"issue":"8","key":"10.1016\/j.clbc.2024.05.001_bib0024","first-page":"1177","article-title":"Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer","volume":"8","author":"Tarantino","year":"2022","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2024.05.001_bib0025","first-page":"e22330","article-title":"Impact of human epidermal growth factor receptor 2 (HER2) low status in response to neoadjuvant chemotherapy in early breast cancer","volume":"14","author":"Alves","year":"2022","journal-title":"Cureus"},{"issue":"4","key":"10.1016\/j.clbc.2024.05.001_bib0026","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.4143\/crt.2022.1633","article-title":"Prognostic value of the evolution of HER2-low expression after neoadjuvant chemotherapy","volume":"55","author":"Ma","year":"2023","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.clbc.2024.05.001_bib0027","first-page":"327","article-title":"Comparison of the pCR rate and DFS among breast cancer patients with different hormone receptor and HER2 statuses","volume":"15","author":"Jin","year":"2023","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"13","key":"10.1016\/j.clbc.2024.05.001_bib0028","doi-asserted-by":"crossref","first-page":"8026","DOI":"10.1245\/s10434-022-12369-4","article-title":"Clinical, pathological complete response, and prognosis characteristics of HER2-low breast cancer in the neoadjuvant chemotherapy setting: a retrospective analysis","volume":"29","author":"Shao","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"Supplement 5","key":"10.1016\/j.clbc.2024.05.001_bib0029","article-title":"HER2-01 clinical and molecular characteristics of HER2-low\/zero early stage triple-negative breast cancer","volume":"83","author":"Yam","year":"2023","journal-title":"Cancer Res"},{"issue":"Supplement 4","key":"10.1016\/j.clbc.2024.05.001_bib0030","first-page":"PS4","article-title":"Her2 low status and response to neoadjuvant chemotherapy in Her2 negative early breast cancer","volume":"81","author":"RaphaeliSilva Mattos","year":"2021","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.clbc.2024.05.001_bib0031","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1177\/10815589231151232","article-title":"Comparison of clinicopathological characteristics and response to neoadjuvant systemic therapy in patients with HER2-low-positive and HER2-zero breast cancer","volume":"71","author":"Shi","year":"2023","journal-title":"J Investig Med"},{"key":"10.1016\/j.clbc.2024.05.001_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.996434","article-title":"Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world","volume":"9","author":"Di Cosimo","year":"2022","journal-title":"Front Mol Biosci"},{"issue":"1","key":"10.1016\/j.clbc.2024.05.001_bib0033","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12916-022-02346-9","article-title":"Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status","volume":"20","author":"Zhang","year":"2022","journal-title":"BMC Med"},{"issue":"Supplement 4","key":"10.1016\/j.clbc.2024.05.001_bib0034","first-page":"1","article-title":"HER2-low positive status and breast cancer heterogeneity: from real world to gene expression data","volume":"108","author":"Di Cosimo","year":"2022","journal-title":"Tumori Journal"},{"issue":"6","key":"10.1016\/j.clbc.2024.05.001_bib0035","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/jjco\/hyad009","article-title":"HER2-low status may predict poor neoadjuvant chemotherapy response in HR-negative breast cancer: a real-world multicenter study","volume":"53","author":"Xu","year":"2023","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2024.05.001_bib0036","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcms.2010.11.001","article-title":"Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias","volume":"39","author":"Knobloch","year":"2011","journal-title":"J Craniomaxillofac Surg"},{"issue":"20","key":"10.1016\/j.clbc.2024.05.001_bib0037","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.clbc.2024.05.001_bib0038","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2024.05.001_bib0039","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"25","author":"Wolff","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clbc.2024.05.001_bib0040","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3390\/cancers13051015","article-title":"The exciting new field of HER2-low breast cancer treatment","volume":"13","author":"Eiger","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clbc.2024.05.001_bib0041","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"9","key":"10.1016\/j.clbc.2024.05.001_bib0042","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"issue":"17","key":"10.1016\/j.clbc.2024.05.001_bib0043","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.3390\/cancers15174264","article-title":"Oncotype Dx score, HER2 low expression, and clinical outcomes in early-stage breast cancer: a national cancer database analysis","volume":"5","author":"Roy","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clbc.2024.05.001_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.103962","article-title":"Survival differences between HER2-0 and HER2-low-expressing breast cancer-a meta-analysis of early breast cancer patients","volume":"185","author":"Yang","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clbc.2024.05.001_bib0045","article-title":"Clinicopathologic characteristics and prognostic significance of HER2-low expression in patients with early breast cancer: a systematic review and meta-analysis","volume":"13","author":"Tong","year":"2023","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2024.05.001_bib0046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.clbc.2024.05.001_bib0047","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s12282-021-01303-3","article-title":"The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status","volume":"29","author":"Horisawa","year":"2022","journal-title":"Breast Cancer"},{"issue":"Suppl 2","key":"10.1016\/j.clbc.2024.05.001_bib0048","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.annonc.2021.03.036","article-title":"HER2-low vs HER2-zero metastatic breast carcinoma: a clinical and genomic descriptive analysis","volume":"32","author":"Bayona","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2024.05.001_bib0049","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","article-title":"Mechanisms of endocrine resistance in breast cancer","volume":"62","author":"Osborne","year":"2011","journal-title":"Annu Rev Med"},{"issue":"4","key":"10.1016\/j.clbc.2024.05.001_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2021.7239","article-title":"Examination of low ERBB2 protein expression in breast cancer tissue","volume":"8","author":"Fernandez","year":"2022","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2024.05.001_bib0051","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41523-021-00343-4","article-title":"Evolution of HER2-low expression from primary to recurrent breast cancer","volume":"7","author":"Miglietta","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.clbc.2024.05.001_bib0052","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejca.2021.12.022","article-title":"Evolution of low HER2 expression between early and advanced-stage breast cancer","volume":"163","author":"Tarantino","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2024.05.001_bib0053","first-page":"281","article-title":"Can patients with HER2-low breast cancer benefit from anti-HER2 therapies? a review","volume":"15","author":"Wang","year":"2023","journal-title":"Review Breast Cancer (Dove Med Press)"},{"issue":"16 suppl","key":"10.1016\/j.clbc.2024.05.001_bib0054","doi-asserted-by":"crossref","first-page":"TPS623","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS623","article-title":"TRIO-US B-12 TALENT: phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early-stage breast cancer","volume":"40","author":"Hurvitz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clbc.2024.05.001_bib0055","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","article-title":"ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer","volume":"34","author":"Tarantino","year":"2023","journal-title":"Ann Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820924001149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820924001149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T07:50:16Z","timestamp":1726473016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820924001149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1526820924001149"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2024.05.001","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of the Pathological Complete Response Rate and Survival Between HER2-Low and HER2-Zero Breast Cancer in Neoadjuvant Chemotherapy Setting: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2024.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}